<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01297816</url>
  </required_header>
  <id_info>
    <org_study_id>89122</org_study_id>
    <nct_id>NCT01297816</nct_id>
  </id_info>
  <brief_title>Evaluation of Neuroprotective Effect of Minocycline</brief_title>
  <acronym>minocyclin &amp;RD</acronym>
  <official_title>Evaluation of Minocycline Neuro Protective Role in Retinal Detachment Surgery</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shahid Beheshti University of Medical Sciences</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shahid Beheshti University of Medical Sciences</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This process appears as a incredible and progressive event that will not stop till
      reattachment of RPE and neurosensory retina happened .

      Process of degeneration begins from first hours of RD (Retinal Detachment) establishment
      Neuroprotection of photoreceptor following RD is a novel and debatable discussion encountered
      in recent years .

      How to stop this phenomena and neuroprotective agent role in this issue are a new interest of
      researcher.

      In the study the investigators are planning to perform a clinical trial to demonstrate the
      minocycline neuroprotective effect in a double blind design as this impact has been
      implicated previously in a animal study
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>December 2010</start_date>
  <completion_date type="Anticipated">April 2011</completion_date>
  <primary_completion_date type="Anticipated">December 2010</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>BCVA</measure>
    <time_frame>changes of BCVA in 3 month</time_frame>
    <description>outcome method of measurement: Snellen chart</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>finding of ERG changes</measure>
    <time_frame>3 months</time_frame>
    <description>outcome method of measurement: ERG( testes)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>finding of OCT changes</measure>
    <time_frame>3 months</time_frame>
    <description>outcome method of measurement: OCT</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>finding of FAF changes</measure>
    <time_frame>3 months</time_frame>
    <description>outcome method of measurement: FAF( testes)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <condition>Retinal Detachment</condition>
  <arm_group>
    <arm_group_label>placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>100mg-</description>
  </arm_group>
  <arm_group>
    <arm_group_label>minocyclin</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>100mg,BD, fo three month</description>
    <arm_group_label>placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Minocycline</intervention_name>
    <description>100mg</description>
    <arm_group_label>minocyclin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  age over 8 years old

          -  gender of both sex

          -  normal liver and renal function

          -  informed consent received from all patients

          -  no pregnancy and no lactation

          -  minimal sun exposure

        Exclusion Criteria:

          -  old RD

          -  diabetic retina

          -  previous retinal surgery CRF&amp; liver disfunction RD + PVR &gt; B Hyper sensitivity to
             tetracycline History previous MPC or PRP Patients unsuccessful SB (retina is off )
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>8 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Labbafinejad medical center</name>
      <address>
        <city>Tehran</city>
        <country>Iran, Islamic Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mohsen Azarmina, Associate Professor</last_name>
      <phone>00982122585952</phone>
      <email>labbafi@hotmail.com</email>
    </contact>
    <investigator>
      <last_name>Mohsen Azarmina, Associate Professor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Iran, Islamic Republic of</country>
  </location_countries>
  <verification_date>December 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 19, 2011</study_first_submitted>
  <study_first_submitted_qc>February 16, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 17, 2011</study_first_posted>
  <last_update_submitted>February 16, 2011</last_update_submitted>
  <last_update_submitted_qc>February 16, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 17, 2011</last_update_posted>
  <responsible_party>
    <name_title>Mohsen Azarmina</name_title>
    <organization>Ophthalmic Research center</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Retinal Detachment</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Minocycline</mesh_term>
    <mesh_term>Neuroprotective Agents</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

